



Date: February 01, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Newspaper Publication of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023 as published in “Financial Express” and "Jansatta" on February 01, 2024.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711

● **BOOST FROM A HEALTHY LOAN GROWTH**

BoB beats profit estimates in Q3

Shares hit 52-week high in the day

SACHIN KUMAR
Mumbai, January 31

BANK OF BARODA on Wednesday reported an 18.8% rise in net profit to ₹4,579 crore in the third quarter of current financial year, aided by a healthy loan growth. The public sector lender beat expectations as Bloomberg analysts expected the bank to post ₹4,127 crore net profit in the quarter.


Net interest income, the difference between interest earned and paid, rose 2.6% to ₹11,101 crore from ₹10,818 crore a year ago. Net interest margin (NIM) contracted to 3.23% compared to 3.54% a year ago.

"Going forward, in January-March, generally we see a lot of traction in terms of deposit growth. We had given a guidance of 12-14% growth for deposits and we hope to maintain around 12% deposit growth to maintain advances growth of 14-16%," said Debadatta Chand, MD & CEO, Bank of Baroda, in an earnings call on Wednesday.

The bank improved its asset quality during the quarter as gross non-performing assets


REPORT CARD

Bank of Baroda financials



BANK OF BARODA

Intra-day on BSE (₹), Jan 31



(NPAs) declined to 3.08% of gross loans by the end of December 2023 from 4.53% a year ago. Similarly, net NPAs or bad loans came down to 0.70% from 0.99% a year ago.

However, the bank's capital adequacy ratio moderated to 14.72% against 14.93% at the end of December 2022.

During the December quarter of FY24, the bank made a contingent provision of ₹50.49 crore in respect to its investment in alternate investment fund (AIF) pursuant to an RBI circular dated December 19, 2023.

The lender witnessed a

strong loan growth as its domestic advances increased by 13.4% year-on-year to ₹8.62 trillion as of December 31, 2023, while global advances grew 13% to ₹10.49 trillion. Domestic deposits increased by 6.3% to ₹10.67 trillion while international deposits grew 22.1% to ₹1.77 trillion.

Retail advances grew by 22%, led by growth in auto loan, home loan, personal loan, mortgage loan and education loan. Corporate advances registered a growth of 10.2% to reach ₹3.62 trillion as of December end.

Banks' credit growth slows to 20% in December

FE BUREAU
Mumbai, January 31

BANKS' NON-FOOD CREDIT grew 20.1% year-on-year (y-o-y) to ₹159.18 trillion as of December 29, lower than 21% in November, RBI's sectoral deployment of credit data showed. Excluding the merger impact of HDFC twins, credit offtake was up 16%.

Bank credit to agriculture and allied activities was up nearly 20% y-o-y to ₹19.94 trillion in December, higher than 12% a year ago, while credit to industry segment rose 9% y-o-y to ₹36.64 trillion. Within the industry segment, credit to large corporates rose 7% y-o-y to ₹26.70 trillion.

Among the services sector, loans to NBFCs rose 15% to ₹15.20 trillion, sharply lower than the 34% y-o-y growth a year ago. This gains importance as the RBI had in November hiked risk weights on bank loans to NBFCs by 25% over and above the risk weight associated with the given external rating in all cases where the risk weight was below 100%.

RBI had also hiked risk weight on unsecured consumer credit, including credit card loans to 125% from 100%. However, data showed that while consumer durable loans' growth moderated to 14% y-o-y to ₹24,312 crore in December from 28% a year ago.

Import duty on mobile phone parts slashed

The import duty on inputs or parts that are used in manufacturing of these components has been reduced to nil from 7.5% and 15%.

"This rationalisation of customs duties brings much-needed certainty and clarity for the industry and in the customs processes," communications and IT minister Ashwini Vaishnaw said. "I thank the Prime Minister and the finance minister for this step towards strengthening the mobile phone manufacturing ecosystem," he added.

Minister of state for electronics and IT Rajeev Chandrasekhar said: "Competitiveness and scale are critical to India's transformation into a global hub for electronics manufacturing and exports, and pivot into export-led manufacturing."

According to a study by the India Cellular and Electronics Association (ICEA), higher tariffs in India result in an overall loss of competitiveness of about 6% to 7% compared with Vietnam and China.

The mobile phone and electronics companies welcomed the announcement.

"The adjustment of BCD (basic customs duty) to 10% on parts of mobile phones and mechanics and die-cut parts and 0% on inputs of mechanics represents the start of a paradigm shift in the policy orientation of the government towards export-led growth and competitiveness," said Pankaj Mohindroo, chairman at ICEA. Electronics industry association MAIT echoed the view, stating that the duty reduction will improve the competitiveness of India in the global market.

"The duty cut can help drop smartphone prices by 3-5%, empowering the consumers and making the devices affordable, especially in the entry and budget segments," Tarun Pathak, research direc-

ASHWINI VAISHNAW,
IT MINISTER

THIS RATIONALISATION OF DUTIES BRINGS MUCH-NEEDED CERTAINTY AND CLARITY FOR THE INDUSTRY AND IN THE CUSTOMS PROCESSES



RAJEEV CHANDRASEKHAR,
MoS FOR ELECTRONICS & IT

COMPETITIVENESS AND SCALE ARE CRITICAL FOR INDIA TO TURN INTO A GLOBAL HUB FOR ELECTRONICS AND EXPORTS



tor at Counterpoint India, said.

According to market tracker firm International Data Corp (IDC), the average selling price (ASP) of smartphones in India hit a high of \$253 (₹21,000), with 5% sequential and 12% year-on-year growth in the July-September quarter.

Navkender Singh, associate vice-president at IDC India, said: "Looking at the current list, very few basic components seem to be covered. Hence, the end pricing can be slashed anywhere in range of 1-2%, or more realistically, this would not impact the consumer pricing at all."

Faisal Kawoosa, chief analyst at Techarc, said: "OEMs

(original equipment makers) might not be keen to pass the cost reduction to end consumers. Rather, they would use this either in increasing channel margins or using it somewhere else."

In 2018, the basic customs duty on mobile phone components in other categories was raised by the government to 15% from 5% under the Phased Manufacturing Programme (PMP). The same led to issues of misinterpretations and created inadvertent complications for the mobile phone industry.

However, trade body Global Trade Research Initiative (GTRI) was critical of the move to reduce the import duties. "The duty cut will have no impact on improving export competitiveness of mobile phones made in India as all inputs, parts, and components used in the making of mobile phones for exports can already be imported at zero duty under various government schemes like SEZ (special economic zone) and Advance authorisation," it said.

The think tank said firms like Apple are already using these schemes. Apple has partnered with contract manufacturers like Foxconn, Pegatron and Tata-owned Wistron to make iPhones in the country.

Currently, mobile phones constitute over 52% of electronics exports. The continuous improvement is owing to the impact of the production-linked incentive (PLI) scheme.

India's smartphone exports jumped 100% in FY23 to \$11 billion (₹90,000 crore) over FY22. The industry expects exports of \$15 billion (around ₹1.2 trillion) in FY24, largely led by Samsung and Apple. Exports will form 30% of the total production of \$49-50 billion (around ₹4.1 trillion) in the current financial year ending March.

Wipro to lay off hundreds of staff

The spokesperson further said the IT services firm is committed to investing in people, processes and technology to drive better client and employee experiences and enhance productivity and agility across the organisation to meet fast-evolving client and market needs.

The challenge before Wipro chief executive officer Thierry Delaporte is to balance margin and growth.

Wipro's margins came in at 16% during the October-December quarter. Tata Consultancy Services, Infosys and HCLTech reported margins of 25%, 20.5% and 19.8%, respectively.

Sources said that Wipro is working big time on automation and has committed to invest \$1 billion on artificial intelligence (AI) technologies over the next three years. It has launched an AI-first innovation ecosystem, Wipro ai360, to integrate AI into every platform, tool and solution used internally and offered to its clients.

"We are aligning our operational structure, skilling academies and GenAI capabilities to market demand, client expectations and also to the evolving process landscape inside Wipro. We are one of the biggest customers of our ai360 ecosystem. These transformation programmes and margin expansion initiatives are delivering results," Wipro chief operating officer Amit Choudhary had said during the Q3 earnings call.

Choudhary had added: "Our goals remain profitable growth, delivery excellence and internal capability development, all leading towards sustainable success."

RBI Digital Payments Index rises in September

FE BUREAU
Mumbai, January 31

THE RESERVE BANK of India (RBI) Digital Payments Index rose to 418.77 in September 2023 from 395.57 in March 2023, according to a press release on Wednesday.

Since January 2021, RBI has been publishing a composite digital payments index with March 2018 as base to capture the extent of digitisation of payments across the country. The index stood at 377.46 in September 2022.

"The RBI-DPI index has increased across all parameters and was driven particularly by growth in payment enablers, payment performance and consumer centricity across the country over the period," the press release said.

The index comprises five parameters that enable measurement of deepening and penetration of digital payments in the country over different time periods. These parameters are payment enablers, payment infrastructure — demand-side factors, payment infrastructure — supply-side factors, payment performance, and consumer centricity.

Recoveries may be double of slippages in FY25: PNB

SACHIN KUMAR
Mumbai, January 31

PUNJAB NATIONAL BANK (PNB) is expecting recoveries from bad loans to double the slippages amount in the next financial year. The higher recovery target comes amid encouraging recoveries made by the lender in the current fiscal.

The bank managed to recover ₹15,881 crore from bad loans for the first nine months of FY24, which is over three times of slippages. Total slippages were at ₹4,551 crore during the period.

"For the next financial year, we will set a target that whatever will be the slippages, recovery should be double that amount because we are having so much of stock — ₹60,000 crore is gross NPA," said Atul Kumar Goel, managing director and chief executive officer, in an earnings call.

In the third quarter also, the recovery was higher than slippages, he added. Total slippages in the third quarter of FY24 stood at ₹1,793 crore while recoveries were at ₹6,387 crore.

Goel said the bank has taken various measures to boost its recovery, and is not entirely dependent on the

THE STORY SO FAR

₹ 15,881 crore

recovery in first nine months of FY24

₹ 4,551 crore

Total slippages in first nine months of FY24

₹ 1,793 cr

Total slippages in Q3

₹ 6,387 cr

recoveries in Q3

₹ 1,831 cr

recovery from NCLT of the total in Q3



₹ 5,533 cr

recovered in Q2

₹ 1,826 cr

slippages in Q2

National Company Law Tribunal (NCLT) for the same.

"Recovery from the NCLT is just one-third of total recoveries. Out of ₹6,387 crore which we recovered in the December quarter, the recovery from the NCLT was only ₹1,831 crore," Goel said.

The bank maintained the trend of higher recovery in the second quarter as well. It recovered ₹5,533 crore in the July-September period while slippages stood at ₹1,826 crore.

Apart from boosting its recovery, the state-run lender

has also been able to improve its asset quality.

Its gross non-performing assets (GNPA) ratio improved by 352 basis points year-on-year to 6.24% as on December 2023, from 9.76% in the year-ago period.

The NNPA ratio improved by 234 bps on a y-o-y basis to 0.96% from 3.30%.

Gross NPAs stood at ₹60,371 crore against ₹65,563.1 crore in the previous quarter, while net NPAs came in at ₹8,815.8 crore, compared with ₹13,114 crore.

Sun Pharmaceutical Industries Limited						
Regd Office: SPARC, Tandajja, Vadodara - 390012, Gujarat, INDIA						
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063						
Tel No. +91 22 43244324 CIN: L24230G11993PLC019050 Website: www.sunpharma.com						
Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2023						
(₹ in Million)						
Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2023 Unaudited	30.09.2023 Unaudited	31.12.2022 Unaudited	31.12.2023 Unaudited	31.12.2022 Unaudited	31.03.2023 Audited
Total revenue from operations	123,807.0	121,924.1	112,409.7	365,139.5	329,550.1	438,856.8
Profit / (Loss) for the period (before Tax, Exceptional items)	30,701.6	27,908.8	24,714.7	86,650.5	71,687.4	95,798.8
Profit / (Loss) for the period before tax (after Exceptional items)	30,003.5	27,908.8	24,714.7	82,723.7	71,687.4	94,084.3
Net Profit / (loss) after taxes, share of profit / (loss) of associates and joint venture and non-controlling interests	25,237.5	23,755.1	21,660.1	69,218.0	64,891.1	84,735.8
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	29,854.8	26,043.5	29,291.4	78,121.5	89,475.3	107,695.1
Equity Share Capital	2,399.3	2,399.3	2,399.3	2,399.3	2,399.3	2,399.3
Other Equity	N.A.	N.A.	N.A.	N.A.	N.A.	557,554.5
Earnings Per Share (of ₹ 1/- each) (not annualised for quarters)						
₹ Basic:	10.5	9.9	9.0	28.8	27.0	35.3
₹ Diluted:	10.5	9.9	9.0	28.8	27.0	35.3

Notes:
1. The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2024.
2. Additional information on standalone financial results is as follows:

Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2023 Unaudited	30.09.2023 Unaudited	31.12.2022 Unaudited	31.12.2023 Unaudited	31.12.2022 Unaudited	31.03.2023 Audited
Total revenue from operations	50,737.5	50,962.1	46,457.5	146,360.3	148,639.2	208,121.4
Profit/(loss) for the period (before Tax) (after Exceptional items)	7,514.7	9,065.2	5,060.8	20,478.7	27,713.2	17,410.5
Net Profit / (loss) for the period (after tax)	7,213.1	8,886.3	4,867.3	19,905.8	27,115.4	16,907.2
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	7,275.7	8,550.1	4,993.3	19,865.6	26,595.9	16,797.1

3. The above is an extract of the detailed format of unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and on the Company's website www.sunpharma.com.

Mumbai, January 31, 2024

For and on behalf of the Board
Dilip S. Shanghvi
Managing Director

Mankind Pharma Limited							
Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600							
Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700							
Email: investors@mankindpharma.com, Website: www.mankindpharma.com, CIN: L74899DL1991PLC044843							
Extract of unaudited financial results for the quarter and nine months ended December 31, 2023							
(₹ in Lacs except as stated otherwise)							
S. No.	Particulars	Consolidated					
		For the quarter ended		For the nine months ended		For the Year ended	
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	260,695.89	270,809.90	209,093.03	789,367.54	669,676.60	874,943.30
2	Profit for the period/year before tax	56,232.92	64,098.71	37,898.93	182,778.18	129,395.38	167,123.91
3	Profit for the period/year after tax	45,981.37	51,117.67	29,571.95	146,517.88	101,597.76	130,967.58
4	Total comprehensive income for the period/ year	46,556.60	50,905.98	29,382.74	146,551.79	101,019.09	130,778.83
5	Paid-up equity share capital	N.A.	N.A.	N.A.	N.A.	N.A.	4,005.88
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	N.A.	N.A.	739,516.40
7	Earnings per equity share of face value of ₹ 1/- each	11.33	12.51	7.09	35.99	24.87	32.00
	- Basic EPS (in ₹)	11.31	12.49	7.09	35.94	24.87	32.00
	- Diluted EPS (in ₹)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)

The key standalone financial information is as under: (₹ in Lacs except as stated otherwise)

S. No.	Particulars	For the quarter ended			For the nine months ended		For the Year ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	235,856.62	245,334.52	193,623.10	711,212.27	625,503.15	812,715.32
2	Profit for the period/year before tax	57,635.16	61,196.24	32,563.69	171,470.71	120,740.31	156,283.66
3	Profit for the period/year after tax	48,707.33	47,288.44	24,887.32	136,923.99	96,727.00	124,825.80
4	Total comprehensive income for the period/year	49,399.98	46,932.51	24,606.02	136,991.74	95,870.94	124,339.91

Notes:
1. The above is an extract of the detailed format of Quarterly Unaudited Consolidated and Standalone Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.mankindpharma.com.
2. The Unaudited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on January 31, 2024.

For and on behalf of
MANKIND PHARMALIMITED

Sd/-
Ramesh Juneja
Chairman and Whole Time Director
DIN: 00283399

Place: New Delhi
Date: January 31, 2024

